Pharmaceutical Technology
AUGUST 5, 2022
Clinical trial design continues to increase in complexity, and temperature-controlled logistics – in particular cold chain and frozen and associated supply chains – must also advance to keep pace with technological developments. Temperature-controlled clinical trial supply chain.
Pharmaceutical Technology
MARCH 20, 2023
Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinical trials. Clinical trials data for Africa Globally, research has found that 62.2%
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 20, 2022
Running a clinical trial is a complex process that typically involves multiple vendors to obtain everything required, which has been made far more challenging during the global pandemic these past few years. He has spoken at numerous clinical trial conferences worldwide.
Outsourcing Pharma
SEPTEMBER 22, 2021
SmartSignals Supplies is designed to help trial teams get a handle on clinical trial supply chain management to avoid delays, waste, and cost overruns.
Pharmaceutical Technology
OCTOBER 26, 2022
There is no denying that trial complexity is continuing to increase. Several factors in recent years have contributed to this rise including more complex trial designs, the rapid adoption of decentralisation stemming from the pandemic, and larger global trials.
The Pharma Data
SEPTEMBER 15, 2020
Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial.
The Pharma Data
NOVEMBER 26, 2020
Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market.
Client Pharma
DECEMBER 13, 2021
Collaboration provides clinical trial sponsors with access to the world’s most efficient clinical supply processes using a single contract. This will cut supply costs by 50% and reduce clinical supply teams’ efforts by 80%.
Pharmaceutical Technology
DECEMBER 2, 2022
An accurate drug supply forecast is essential for a successful clinical trial. Without it, sponsors risk a shortage of investigative medicinal product (IMP) for patients, resulting in major trial delays. They begin the trial expecting about a 30 percent overage.
The Pharma Data
SEPTEMBER 14, 2020
Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain. Clinical Trails
Pharmaceutical Technology
SEPTEMBER 14, 2022
The Phase I clinical trial that is underway is assessing SY-5609 plus chemotherapy in subjects with pancreatic cancer whose disease has advanced after Folfirinox treatment. .
Client Pharma
SEPTEMBER 18, 2020
Client-Pharma is proud to be a Bronze sponsor at this year’s first-ever Global Clinical Supplies Group – GCSG 2020 Virtual Conference. Join us and other professionals September 21-25 for interactive and engaging workshop discussions, developing best practices in clinical trial supply and fun networking events from the comfort of your home or office.
Client Pharma
SEPTEMBER 18, 2020
Client-Pharma is proud to be a Bronze sponsor at this year’s first-ever Global Clinical Supplies Group – GCSG 2020 Virtual Conference. Join us and other professionals September 21-25 for interactive and engaging workshop discussions, developing best practices in clinical trial supply and fun networking events from the comfort of your home or office.
The Pharma Data
AUGUST 4, 2020
The agreement also puts in place a three year clinical supply agreement for the two companies. Agreement will utilise Oxford Biomedica's LentiVector platform.
The Pharma Data
AUGUST 15, 2021
Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. Pfizer is collaborating with Vivet on the clinical supply of VTX-801 for the Phase 1/2 clinical trial. About GATEWAY – Phase 1/2 Clinical Trial of VTX-801 in Wilson Disease.
The Pharma Data
DECEMBER 14, 2020
The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. 15, 2020 07:15 UTC.
The Pharma Data
JANUARY 10, 2021
Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.
The Pharma Data
DECEMBER 4, 2021
company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. Today, Amazon Web Services, Inc.
The Pharma Data
NOVEMBER 22, 2020
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 23, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep), a DARPin® therapeutic candidate for the potential treatment and prevention of COVID-19.
The Pharma Data
JANUARY 24, 2021
Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. Toronto, Ontario–(Newsfile Corp.
The Pharma Data
OCTOBER 27, 2020
Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.
The Pharma Data
NOVEMBER 18, 2020
Lars Nieba, Interim CEO of Nordic Nanovector, said: “Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. Trial to be paused pending analysis of data and evaluation of plans for further development. OSLO, Norway , Nov.
Expert insights. Personalized for you.
245 
Let's personalize your content